Phases, active trials: Phase 1: 40, Phase 1/2: 5, Phase 2: 15, Phase 3: 28, No phase listed: 10
Boehringer Ingelheim is a privately-held pharmaceutical company with major franchises in respiratory disease, metabolic conditions, and oncology. In respiratory, Ofev (nintedanib) for idiopathic pulmonary fibrosis and other fibrosing ILDs continues expanding into new fibrosing lung conditions, while Spiriva and Spiolto anchor the COPD franchise. In metabolic disease, Jardiance (empagliflozin), co-developed with Eli Lilly, has expanded from type 2 diabetes into heart failure with reduced and preserved ejection fraction, and is advancing into CKD. Their oncology pipeline focuses on novel mechanisms in solid tumors, including KRAS SOS1 inhibitors, KRASG12C inhibitors, and immune cell engagers targeting tumor microenvironment.
- Respiratory (IPF, ILD, COPD)
- Metabolic / cardiovascular (SGLT2, HFpEF)
- Oncology (KRAS, SOS1, tumor microenvironment)
- Immunology / inflammation
- CNS
- Jardiance (empagliflozin): SGLT2, T2D/HF/CKD
- Ofev (nintedanib): FGFR, PDGFR, VEGFR: IPF/ILD
- Gilotrif (afatinib): EGFR/HER2 inhibitor, NSCLC
- BI 1701963: SOS1 inhibitor, KRAS-mutant tumors
- BI 905677: KRASG12C inhibitor
- Spesolimab: IL-36R, generalized pustular psoriasis
A primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With… NCT04886804 | Primary completion moved at least 1 year 2 months later Primary endpoint(s) modified | Recruiting |
14 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People… NCT06151574 | Dec 10, 2026 · Estimated | Phase 3 |
9 more on the Completions page. See the calendar →
Monitor the Boehringer Ingelheim pipeline daily
Get a daily digest when Boehringer Ingelheim registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Active trials |
|---|---|
| Healthy | 14 |
| Obesity | 10 |
| Interstitial Lung Diseases | 4 |
| Neuroendocrine Neoplasms | 4 |
| Small Cell Lung Carcinoma (SCLC) | 4 |
| Solid Tumours | 4 |
| Bronchiectasis | 3 |
| Heart Failure | 3 |
Boehringer Ingelheim's SOS1 inhibitor (BI 1701963) in combination with KRAS G12C inhibitors is a major competitive program for anyone active in KRAS-altered NSCLC or CRC. Their Jardiance expansions into HFpEF and CKD are closely watched by companies developing competing SGLT2 or HF therapeutics.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Boehringer Ingelheim's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: Boehringer Ingelheim may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your Boehringer Ingelheim pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney… NCT07220083 | Recruiting | Trial sites reduced: 316 → 309 locations | 2026-11-14 |
| A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control… NCT07754461 | Recruiting | Trial sites expanded: 101 → 121 locations | 2026-11-14 |
| A Study to Test How Well BI 3000202 is Tolerated by People With Type 1… NCT06878365 | Active, Not Recruiting | Study completion pushed from Dec 7, 2026 to Dec 20, 2029 | 2026-11-14 |
| A Study in People With Overweight or Obesity to Compare How 2 Different… NCT07407348 | Active, Not Recruiting | Study completion pushed from Mar 2, 2027 to Apr 9, 2027 | 2026-11-14 |
| A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary… NCT07926321 | Not Yet Recruiting | Trial sites expanded: 37 → 42 locations | 2026-11-14 |
Each trial page shows every change DataLookout has recorded for that trial.